Testing effectiveness (Phase 2)Study completedNCT02187783
What this trial is testing
LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)
Who this might be right for
Tumors With CDK4/6 Pathway Activation
Novartis Pharmaceuticals 106
Showing 20 of 0 results